| First Author | Gouveia Roque C | Year | 2023 |
| Journal | Sci Adv | Volume | 9 |
| Issue | 9 | Pages | eadd2671 |
| PubMed ID | 36867706 | Mgi Jnum | J:348201 |
| Mgi Id | MGI:7443725 | Doi | 10.1126/sciadv.add2671 |
| Citation | Gouveia Roque C, et al. (2023) CREB3L2-ATF4 heterodimerization defines a transcriptional hub of Alzheimer's disease gene expression linked to neuropathology. Sci Adv 9(9):eadd2671 |
| abstractText | Gene expression is changed by disease, but how these molecular responses arise and contribute to pathophysiology remains less understood. We discover that beta-amyloid, a trigger of Alzheimer's disease (AD), promotes the formation of pathological CREB3L2-ATF4 transcription factor heterodimers in neurons. Through a multilevel approach based on AD datasets and a novel chemogenetic method that resolves the genomic binding profile of dimeric transcription factors (ChIPmera), we find that CREB3L2-ATF4 activates a transcription network that interacts with roughly half of the genes differentially expressed in AD, including subsets associated with beta-amyloid and tau neuropathologies. CREB3L2-ATF4 activation drives tau hyperphosphorylation and secretion in neurons, in addition to misregulating the retromer, an endosomal complex linked to AD pathogenesis. We further provide evidence for increased heterodimer signaling in AD brain and identify dovitinib as a candidate molecule for normalizing beta-amyloid-mediated transcriptional responses. The findings overall reveal differential transcription factor dimerization as a mechanism linking disease stimuli to the development of pathogenic cellular states. |
